An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

NCT02320058 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb